Cargando…

Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials

Objective: Migraine is a complex, prevalent and disabling neurological disorder characterized by recurrent episodes of headache without ideal treatment. We aim to assess the current available evidence of herbal Chuanxiong (Ligusticum chuanxiong Hort. root) formulae for the treatment of migraine acco...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Chun-Shuo, Xu, Qing-Qing, Shi, Yi-Hua, Wang, Yong, He, Zhang-Xin, Zheng, Guo-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036270/
https://www.ncbi.nlm.nih.gov/pubmed/30013473
http://dx.doi.org/10.3389/fphar.2018.00589
_version_ 1783338133438332928
author Shan, Chun-Shuo
Xu, Qing-Qing
Shi, Yi-Hua
Wang, Yong
He, Zhang-Xin
Zheng, Guo-Qing
author_facet Shan, Chun-Shuo
Xu, Qing-Qing
Shi, Yi-Hua
Wang, Yong
He, Zhang-Xin
Zheng, Guo-Qing
author_sort Shan, Chun-Shuo
collection PubMed
description Objective: Migraine is a complex, prevalent and disabling neurological disorder characterized by recurrent episodes of headache without ideal treatment. We aim to assess the current available evidence of herbal Chuanxiong (Ligusticum chuanxiong Hort. root) formulae for the treatment of migraine according to the high-quality randomized controlled trials (RCTs). Methods: English and Chinese electronic databases were searched from their inceptions until March 2017. The methodological quality of included study was assessed by the Cochrane Collaboration risk of bias tool. RCTs with Cochrane risk of bias (RoB) score ≥4 were included in the analyses. Meta-analysis was conducted using RevMan 5.3 software. Publication bias was assessed by funnel plot analysis and Egger's test. Results: Nineteen RCTs with 1832 participants were identified. The studies investigated the Chuanxiong formulae vs. placebo (n = 5), Chuanxiong formulae vs. conventional pharmacotherapy (CP) (n = 13 with 15 comparisons), and Chuanxiong formulae plus CP vs. CP (n = 1). Meta-analysis indicated that Chuanxiong formulae could reduce frequency, duration, days and pain severity of migraine and improve the total clinical efficacy rate (P < 0.05). Adverse event monitoring was reported in 16 out of 19 studies and occurrence rate of adverse event was low. Conclusion: The findings of present study indicated that Chuanxiong formulae exerted the symptom reliefs of for migraine.
format Online
Article
Text
id pubmed-6036270
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60362702018-07-16 Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials Shan, Chun-Shuo Xu, Qing-Qing Shi, Yi-Hua Wang, Yong He, Zhang-Xin Zheng, Guo-Qing Front Pharmacol Pharmacology Objective: Migraine is a complex, prevalent and disabling neurological disorder characterized by recurrent episodes of headache without ideal treatment. We aim to assess the current available evidence of herbal Chuanxiong (Ligusticum chuanxiong Hort. root) formulae for the treatment of migraine according to the high-quality randomized controlled trials (RCTs). Methods: English and Chinese electronic databases were searched from their inceptions until March 2017. The methodological quality of included study was assessed by the Cochrane Collaboration risk of bias tool. RCTs with Cochrane risk of bias (RoB) score ≥4 were included in the analyses. Meta-analysis was conducted using RevMan 5.3 software. Publication bias was assessed by funnel plot analysis and Egger's test. Results: Nineteen RCTs with 1832 participants were identified. The studies investigated the Chuanxiong formulae vs. placebo (n = 5), Chuanxiong formulae vs. conventional pharmacotherapy (CP) (n = 13 with 15 comparisons), and Chuanxiong formulae plus CP vs. CP (n = 1). Meta-analysis indicated that Chuanxiong formulae could reduce frequency, duration, days and pain severity of migraine and improve the total clinical efficacy rate (P < 0.05). Adverse event monitoring was reported in 16 out of 19 studies and occurrence rate of adverse event was low. Conclusion: The findings of present study indicated that Chuanxiong formulae exerted the symptom reliefs of for migraine. Frontiers Media S.A. 2018-06-27 /pmc/articles/PMC6036270/ /pubmed/30013473 http://dx.doi.org/10.3389/fphar.2018.00589 Text en Copyright © 2018 Shan, Xu, Shi, Wang, He and Zheng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shan, Chun-Shuo
Xu, Qing-Qing
Shi, Yi-Hua
Wang, Yong
He, Zhang-Xin
Zheng, Guo-Qing
Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
title Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
title_full Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
title_fullStr Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
title_full_unstemmed Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
title_short Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials
title_sort chuanxiong formulae for migraine: a systematic review and meta-analysis of high-quality randomized controlled trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036270/
https://www.ncbi.nlm.nih.gov/pubmed/30013473
http://dx.doi.org/10.3389/fphar.2018.00589
work_keys_str_mv AT shanchunshuo chuanxiongformulaeformigraineasystematicreviewandmetaanalysisofhighqualityrandomizedcontrolledtrials
AT xuqingqing chuanxiongformulaeformigraineasystematicreviewandmetaanalysisofhighqualityrandomizedcontrolledtrials
AT shiyihua chuanxiongformulaeformigraineasystematicreviewandmetaanalysisofhighqualityrandomizedcontrolledtrials
AT wangyong chuanxiongformulaeformigraineasystematicreviewandmetaanalysisofhighqualityrandomizedcontrolledtrials
AT hezhangxin chuanxiongformulaeformigraineasystematicreviewandmetaanalysisofhighqualityrandomizedcontrolledtrials
AT zhengguoqing chuanxiongformulaeformigraineasystematicreviewandmetaanalysisofhighqualityrandomizedcontrolledtrials